Our Science

Our team deploys state-of-the-art drug discovery modalities to identify novel, first-in-class antivirals for the individual infections we study. These modalities include phenotypic screening in infected cultured cells, biochemical screening in vitro on virus-encoded enzymatic targets and structure-based drug design, as well as combinations of the above approaches. Where appropriate, we also target host factors essential for viral infection.